Evercore ISI Group Downgrades Atara Biotherapeutics to In-Line
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group analyst Michael DiFiore has downgraded Atara Biotherapeutics (NASDAQ:ATRA) from Outperform to In-Line.
November 09, 2023 | 2:38 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Atara Biotherapeutics has been downgraded from Outperform to In-Line by Evercore ISI Group.
The downgrade from Outperform to In-Line by Evercore ISI Group suggests that the analyst believes the stock may perform at the same level as the overall market, rather than outperforming it. This could potentially lead to a decrease in demand for the stock, and subsequently, a decrease in its price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100